Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous
wide range of molecular tumor behavior and a high risk of progression. Early detection and …

Progress in understanding the disease biology and mechanisms of castration resistance led
to significant therapeutic advancements, particularly in the setting of mCRPC in which …

The therapeutic landscape of metastatic hormone sensitive and metastatic castration-
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …

Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men
globally. Despite improvements in the diagnosis and treatment of PCa, a significant …

Background Androgen-targeted therapy and chemotherapy are currently the mainstay of
treatment in metastatic castration resistant prostate cancer (mCRPC). When progression …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Background The tumors of many patients with prostate cancer eventually become refractory
to androgen deprivation therapy with progression to metastatic castration-resistant disease …

Introduction: Advances in clinical research have led to official approval of several new
treatments for metastatic prostate cancer in the last three years: sipuleucel-T, cabazitaxel …

Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant
disease. Although docetaxel is the standard of care for these patients and is associated with …

CONTEXT: Improved understanding of mechanisms underlying metastatic castration-
resistant prostate cancer (mCRPC) progression has led to the recognition of multiple …